Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Pharmaciana: Jurnal Kefarmasian
Jie Yi Tan
Massachusetts College of Pharmacy and Health Sciences
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma Jie Yi Tan; Aadya Jaipuria; Ronny Priefer
Pharmaciana Vol 13, No 2 (2023): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v13i2.24638

Abstract

Vascular endothelial growth factors receptors (VEGFR) inhibitors play a vital role in the treatment of renal cell carcinoma. These are small molecules that predominantly exhibit anti-angiogenesis activity in conjunction with other anti-tumor effects. These drug therapies are approved for the use in patients as frontline agents or adjuvant therapy in renal cell carcinoma. However, VEGFR inhibitors are associated with undesirable adverse events, with some having a more manageable toxicity profile compared to others. As a result, choice of treatment poses a challenge for healthcare providers and patients. Nonetheless, these agents demonstrate improved disease/progression free survival (DFS/PFS) values and remain a critical component in the treatment of kidney cancer.
Co-Authors Aadya Jaipuria Ronny Priefer